BioPharm International Editors

NIH study reveals a new cancer immunotherapy method could be effective against a range of cancers.

FDA finalizes guidance on expedited programs for new drug approvals for treatment of serious and life-threatening conditions.

PacificGMP doubles its GMP production capacity with the addition of a second System 1000 Bioreactor platform.

GE Healthcare introduces the Cytiva Plus Cardiomyocytes, a high fidelity human heart cell model.

Bristol-Myers Squibb announced collaborations with CytomX on probodies and with Incyte in an immunotherapy clinical trial.

GSK selects Genedata Biologics as an R&D data management and workflow-support platform.

The companies aim to discover and develop kinase inhibitors for treating autoimmune disorders.

Rockland Immunochemicals develops new laboratories in Limerick, PA.

The 11th Annual Global Biomanufacturing Study includes a global analysis of 238 biomanufacturers and 178 suppliers in 31 countries.

EMD Millipore expands its Provantage upstream bioproduction services into North America.

Cytovance Biologics and Selexys Pharmaceuticals enter an agreement for development of clinical trial materials.

Kymab receives $40 million investment for clinical development of antibody therapeutics.

Merck KGaA fill-finish expansion in Italy will be completed in 2017.

SAFC offers commercial and pilot-scale continuous-flow capacity.

FDA issues complete response letter for Novartis' RLX030 for acute heart failure.

Meissner moves into its new headquarters in Camarillo, California.

SGS makes two senior appointments at its new GMP/GLP laboratory in Carson, California.

AstraZeneca rejects Pfizer's final offer of $118 billion for a proposed merger of the two companies.

Advanced Scientifics and Chemic Laboratories enter a three-year joint cooperation agreement to collaborate on product development projects.

New manufacturing capacity at the Le Mans, France facility is being used to scale up antibody drug conjugates.

AstraZeneca will collaborate with the Medical Research Council Laboratory of Molecular Biology to fund a range of pre-clinical research projects.

EMA opens registration for it's sixth annual workshop on pediatric drug research and development.

Hillary Clinton will deliver a keynote address at the 2014 BIO International Convention in San Diego.

FDA and EMA release a draft joint proposal on the development of new drugs to treat Gaucher disease in children.

FDA clarifies stability data recommendations for abbreviated new drug applications.

Draft guidance addresses the use of clinical pharmacology studies to determine biosimilarity of biologics.

Eurofins Scientific will acquire ViraCor-IBT Laboratories for $255 million.

KBI Biopharma acquires Merck's microbial process development and manufacturing operations in Colorado.

Shire expands rare disease portfolio with acquisition of Lumena Pharmaceuticals.

Cumberland Pharmaceuticals and Gloria Pharmaceuticals invest $1 million each in Cumberland Emerging Technologies.